Ocean Biomedical, Inc. income statement OCEA

Annual Quarterly

It recorded a net loss of $9.5 million. Diluted earnings per share were -$0.34.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

FY 2025
Mar 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
Research and development
0
-94.7%
0
-96.3%
1
—
Selling, general and administrative
4
-18.4%
4
-60.3%
10
—
Operating income
-4
+23.3%
-4
+62.8%
-10
+36.6%
-16
Net income
-31
-4.6%
-9
+91.7%
-114
-559.4%
-17
Basic EPS
-0.71
+34.7%
-0.34
+92.2%
-4.35
—
Diluted EPS
-0.71
+34.7%
-0.34
+92.2%
-4.35
—
Weighted average shares, basic
43
+60.1%
28
+4.6%
26
—
Weighted average shares, diluted
43
+60.1%
28
+4.6%
26
—
Other measures
Interest coverage
—
—
-204.28x
-23,329.96x
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
OCEA (OTC)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
New York, NY
SEC filer status
, Emerging growth company
SEC CIK
1869974
Former names
Ocean Biomedical, Inc./DE (until Feb 15, 2023); Aesther Healthcare Acquisition Corp. (until Feb 14, 2023)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.